ReNeuron Group plc Appointment of Joint Broker (2550Q)

TIDMRENE

RNS Number : 2550Q

ReNeuron Group plc

25 February 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

Appointment of Joint Broker

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Allenby Capital Limited ("Allenby") as joint corporate broker, with immediate effect to work alongside the Company's existing nominated adviser and joint broker, Stifel Nicolaus Europe Limited.

Michael Hunt, Chief Financial Officer of ReNeuron, commented: "The Company is pleased to appoint Allenby as its joint corporate broker, which, together with the appointment of Walbrook PR as the Company's new investor relations and PR adviser, will further broaden our investor outreach activities, particularly with regards to private client brokers and retail investors."

Contacts:

 
 ReNeuron                                                          www.reneuron.com/investors 
 Olav Hellebø, Chief Executive Officer                                   Via Walbrook PR 
 Michael Hunt, Chief Financial Officer 
 
 Stifel Nicolaus Europe Limited (NOMAD 
  and Joint Broker) 
  Ben Maddison, Stewart Wallace                                           [phone] 
 
 Allenby Capital Limited (Joint Broker) 
  James Reeve/George Payne (Corporate 
  Finance) 
  Tim Sohal (Sales & Corporate Broking)                                   [phone] 
 
 Walbrook PR (Media & Investor Relations)      [phone] or [e-mail] 
  Paul McManus, Alice Woodings                              [phone] / +44 (0)7407 
                                                                                      804 654 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPQZLFLFLLEBBV

(END) Dow Jones Newswires

February 25, 2021 02:00 ET (07:00 GMT)